Hematopoietic growth factors: Personalization of risks and benefits

Shannon Puhalla, Saveri Bhattacharya, Nancy E. Davidson

Research output: Contribution to journalReview articlepeer-review

Abstract

A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalMolecular oncology
Volume6
Issue number2
DOIs
StatePublished - Apr 2012

Keywords

  • Erythropoietin stimulating agents (ESAs)
  • Granulocyte colony stimulating factors (GCSF)
  • Pegfilgastrim

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Hematopoietic growth factors: Personalization of risks and benefits'. Together they form a unique fingerprint.

Cite this